Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition

Bibliography

• Lawes CM, Vander HS, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008;371:1513-18
   PubMed Web of Science ®Google Scholar
• Mendis S, Puska P, Norrvin B. editors. Global atlas on cardiovascular disease prevention and control. World Health Organization, Geneva; 2011
   Google Scholar
• Ruilope LM. Current challenges in the clinical management of hypertension. Nat Rev Cardiol 2011;9:267-75
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
   PubMed Web of Science ®Google Scholar
• Perera GA. Hypertensive vascular disease; description and natural history. J Chronic Dis 1955;1:33-42
   PubMedGoogle Scholar
• Ruilope LM. Can effectiveness of hypertension management be improved? Expert Rev Cardiovasc Ther 2013; In press
   PubMedGoogle Scholar
• Ferdinand K, Saini R, Lewin A, et al. Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone. Am J Hypertens 2001;14(8 Pt 1):788-93
   PubMed Web of Science ®Google Scholar
• Campese VM, Lasseter KC, Ferrario CM, et al. Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. Hypertension 2001;38:1342-8
   PubMed Web of Science ®Google Scholar
• Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004;17(2):103-11
   PubMed Web of Science ®Google Scholar
• Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8
   PubMed Web of Science ®Google Scholar
• Pandey KN. Biology of natriuretic peptides and their receptors. Peptides 2005;26:901-32
   PubMed Web of Science ®Google Scholar
• Gardner DG, Chen S, Glenn DJ, et al. Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. Hypertension 2007;49:419-26
   PubMed Web of Science ®Google Scholar
• Bevan EG, Connell JM, Doyle J, et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992;10:607-13
   PubMed Web of Science ®Google Scholar
• Richards AM, Wittert GA, Crozier IG, et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993;11:407-16
   PubMed Web of Science ®Google Scholar
• Ando S, Rahman MA, Butler GC, et al. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 1995;26:1160-6
   PubMed Web of Science ®Google Scholar
• Ferro CJ, Spratt JC, Haynes et al. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 1998;97:2323-30
   PubMed Web of Science ®Google Scholar
• Campbell DJ. Vasopeptidase inhibition: a double-edged sword? Hypertension 2003;41:383-9
   PubMed Web of Science ®Google Scholar
• Ksander GM, Ghai RD, de Jesus R, et al. Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. J Med Chem 1995;38:1689-700
   PubMed Web of Science ®Google Scholar
• Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor Neprilysin inhibitor (ARNI). J Clin Pharmacol 2010;50:401-14
   PubMed Web of Science ®Google Scholar
• Fryer RM, Segreti J, Banfor PN, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 2008;153:947-55
   PubMed Web of Science ®Google Scholar
• Kobalava Z, Averkov O, Meray I, et al. Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term treatment with LCZ696 in heart failure patients: effect on ANP, BNP, NT-proBNP and cGMP. Eur Heart J 2011;32(Abstract Suppl):784-5
   PubMedGoogle Scholar
• Steckelings UM, Paulis L, Namsolleck P, Unger T. AT2 receptor agonists: hypertension and beyond. Curr Opin Nephrol Hypertens 2012;21:142-6
   PubMed Web of Science ®Google Scholar
• Gwathmey TM, Alzayadneh EM, Pendergrass KD, Chappel MC. Novel roles of nuclear angiotensin receptors and signaling mechanisms. Am J Physiol Regul Integr Comp Physiol 2012;302:R518-30
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weaber M, et al. For the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
   PubMed Web of Science ®Google Scholar
• Solomon SD, Zelenkofske S, McMurray JJ, et al. Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005;352:2581-8
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Holman RR, Haffner SM, et al. NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-90
   PubMed Web of Science ®Google Scholar
• Sawada T, Yamada H, Dahlöf B, et al. KYOTO HEART Study Group. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2009;30:2461-9
   PubMed Web of Science ®Google Scholar
• Mochizuki S, Dahlöf B, Shimizu M, et al. Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007;369:1431-9
   PubMed Web of Science ®Google Scholar
• Viberti G, Wheeldon NM; MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-8
   PubMed Web of Science ®Google Scholar
• Segura J, Ruilope LM. Dual-acting angiotensin-receptor Neprilysin inhibition. Curr Hypertens Rep 2011;13:74-8
   PubMed Web of Science ®Google Scholar
• Burnett JC Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens 1999;17(Suppl 1):S37-43
   Google Scholar
• Fryer RM, Segreti J, Banfor PN, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 2008;153:947-55
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Dukat A, Böhm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and Neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010;375:1255-66
   PubMed Web of Science ®Google Scholar
• Kobalava Z, Kotovskaya Y, Meray I, et al. Clinic blood pressure in stable heart failure patients treated with the dual-acting Neprilysin and angiotensin receptor inhibitor LCZ696. Eur Heart J 2011;32(Abstract Suppl):788
   PubMedGoogle Scholar
• Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor Neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387-95
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302
   PubMed Web of Science ®Google Scholar
• Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-18
   PubMed Web of Science ®Google Scholar
• Granger CB, McMurray JJ, Yusuf S, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17
   PubMed Web of Science ®Google Scholar
• Zannad F, McMurray JJ, Krum H, et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Ostergren J, Swedberg K, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362(9386):767-71
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847
   PubMed Web of Science ®Google Scholar
• Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993;153(8):937-42
   PubMed Web of Science ®Google Scholar
• Anand IS, Fisher LD, Chiang YT, Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107(9):1278-83
   PubMed Web of Science ®Google Scholar
• Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356:615-20
   PubMed Web of Science ®Google Scholar
• Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation 2002;106:920-6
   PubMed Web of Science ®Google Scholar
• A Multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of lcz696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction. Available from: http://clinicaltrials.gov/ct2/show/NCT01035255 [Access 13 January 2013]
   Google Scholar
• Martínez-Sellés M, García Robles JA, Prieto L, et al. Annual rates of admission and seasonal variations in hospitalizations for heart failure. Eur J Heart Fail 2002;4:779-86
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Stough WG, Abraham WT, et al. OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol 2007;50(8):768-77
   PubMed Web of Science ®Google Scholar
• Quirós López R, García Alegría J, Martín Escalante MD, et al. Prognostic factors and long-term survival after initial diagnosis of heart failure. Med Clin (Barc) 2012;138:602-8
   PubMed Web of Science ®Google Scholar
• Rodríguez-Artalejo F, Banegas Banegas JR, Guallar-Castillón P. Epidemiology of heart failure. Rev Esp Cardiol 2004;57:163-70
   PubMed Web of Science ®Google Scholar
• Cleland JG, Clark AL. Heart failure–does it matter whether LVEF is reduced? Lancet 2012;380:1363-5
   PubMed Web of Science ®Google Scholar
• Cuculi F, Erne P. Combined neutral endopeptidase inhibitors. Expert Opin Investig Drugs 2011;20:457-63
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/ct2/results?term=lcz696
   Google Scholar
• Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-19
   PubMed Web of Science ®Google Scholar